Abstract

ACUTE MYELOID LEUKEMIA AFTER TREATMENT WITH RADIOACTIVE IODINE FOR PAPILLARY THYROID CANCER

Gamal Abdul Hamid*, Safa Shukry and Rasha Abbas

Abstract

Radioactive Iodine (RAI) is widely used in the treatment of thyroid cancer. RAI is used after thyroidectomy to ablate the residual normal thyroid remnant, as adjuvant therapy, and to treat thyroid cancer metastases. Leukemia is a rare complication of 131I therapy, usually occurring after cumulative dosages of more than 800 mCi and with intervals between doses of less than 12 months. It occurs in less than 2% of thyroid cancer patients and is associated with a poor therapeutic response and prognosis. We report the occurrence of acute myelogenous leukemia in a 78-yr-old woman had recurrent papillary thyroid carcinoma and long history with radioiodine therapy. Our patient was died after suffering from pancytopenic myeloid leukemia.

Keywords: Thyroid cancer, Radioiodine, Acute myeloid leukemia.